Cargando…

Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan

Introduction: This manuscript reports on a pilot program focused on implementing pharmacogenetic testing within the framework of an employer-sponsored medical plan at University of Florida (UF) Health. The aim was to understand the challenges associated with program implementation and to gather insi...

Descripción completa

Detalles Bibliográficos
Autores principales: Norris, Madeline, Dalton, Rachel, Alam, Benish, Eddy, Elizabeth, Nguyen, Khoa A., Cavallari, Larisa H., Sumfest, Jill, Wiisanen, Kristin, Cicali, Emily J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482099/
https://www.ncbi.nlm.nih.gov/pubmed/37680199
http://dx.doi.org/10.3389/fgene.2023.1249003
_version_ 1785102113829814272
author Norris, Madeline
Dalton, Rachel
Alam, Benish
Eddy, Elizabeth
Nguyen, Khoa A.
Cavallari, Larisa H.
Sumfest, Jill
Wiisanen, Kristin
Cicali, Emily J.
author_facet Norris, Madeline
Dalton, Rachel
Alam, Benish
Eddy, Elizabeth
Nguyen, Khoa A.
Cavallari, Larisa H.
Sumfest, Jill
Wiisanen, Kristin
Cicali, Emily J.
author_sort Norris, Madeline
collection PubMed
description Introduction: This manuscript reports on a pilot program focused on implementing pharmacogenetic testing within the framework of an employer-sponsored medical plan at University of Florida (UF) Health. The aim was to understand the challenges associated with program implementation and to gather insights into patient attitudes towards PGx testing. Methods: The pilot program adopted a partially preemptive approach, targeting patients on current prescriptions for medications with relevant gene-drug associations. Patients were contacted via phone or through the MyChart system and offered pharmacogenetic testing with no additional direct costs. Results: Of 244 eligible patients, 110 agreed to participate. However, only 61 returned the mailed DNA collection kits. Among these, 89% had at least one potentially actionable genotype-based phenotype. Post-test follow-up revealed that while the majority viewed the process positively, 71% preferred a consultation with a pharmacogenetic specialist for better understanding of their results. Barriers to implementation ranged from fatigue with the healthcare system to a lack of understanding of the pharmacogenetic testing and concerns about privacy and potential misuse of genetic data. Conclusion: The findings underscore the need for clearer patient education on pharmacogenetic results and suggest the importance of the role of pharmacogenetic-trained pharmacists in delivering this education. They also highlight issues with relying on incomplete or inaccurate medication lists in patients’ electronic health record. The implementation revealed less obvious challenges, the understanding of which could be beneficial for the success of future preemptive pharmacogenetic implementation programs. The insights from the pilot program served to bridge the information gap between patients, providers, and pharmacogenetic -specialists, with the ultimate goal of improving patient care.
format Online
Article
Text
id pubmed-10482099
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104820992023-09-07 Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan Norris, Madeline Dalton, Rachel Alam, Benish Eddy, Elizabeth Nguyen, Khoa A. Cavallari, Larisa H. Sumfest, Jill Wiisanen, Kristin Cicali, Emily J. Front Genet Genetics Introduction: This manuscript reports on a pilot program focused on implementing pharmacogenetic testing within the framework of an employer-sponsored medical plan at University of Florida (UF) Health. The aim was to understand the challenges associated with program implementation and to gather insights into patient attitudes towards PGx testing. Methods: The pilot program adopted a partially preemptive approach, targeting patients on current prescriptions for medications with relevant gene-drug associations. Patients were contacted via phone or through the MyChart system and offered pharmacogenetic testing with no additional direct costs. Results: Of 244 eligible patients, 110 agreed to participate. However, only 61 returned the mailed DNA collection kits. Among these, 89% had at least one potentially actionable genotype-based phenotype. Post-test follow-up revealed that while the majority viewed the process positively, 71% preferred a consultation with a pharmacogenetic specialist for better understanding of their results. Barriers to implementation ranged from fatigue with the healthcare system to a lack of understanding of the pharmacogenetic testing and concerns about privacy and potential misuse of genetic data. Conclusion: The findings underscore the need for clearer patient education on pharmacogenetic results and suggest the importance of the role of pharmacogenetic-trained pharmacists in delivering this education. They also highlight issues with relying on incomplete or inaccurate medication lists in patients’ electronic health record. The implementation revealed less obvious challenges, the understanding of which could be beneficial for the success of future preemptive pharmacogenetic implementation programs. The insights from the pilot program served to bridge the information gap between patients, providers, and pharmacogenetic -specialists, with the ultimate goal of improving patient care. Frontiers Media S.A. 2023-08-23 /pmc/articles/PMC10482099/ /pubmed/37680199 http://dx.doi.org/10.3389/fgene.2023.1249003 Text en Copyright © 2023 Norris, Dalton, Alam, Eddy, Nguyen, Cavallari, Sumfest, Wiisanen and Cicali. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Norris, Madeline
Dalton, Rachel
Alam, Benish
Eddy, Elizabeth
Nguyen, Khoa A.
Cavallari, Larisa H.
Sumfest, Jill
Wiisanen, Kristin
Cicali, Emily J.
Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
title Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
title_full Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
title_fullStr Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
title_full_unstemmed Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
title_short Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
title_sort lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482099/
https://www.ncbi.nlm.nih.gov/pubmed/37680199
http://dx.doi.org/10.3389/fgene.2023.1249003
work_keys_str_mv AT norrismadeline lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT daltonrachel lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT alambenish lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT eddyelizabeth lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT nguyenkhoaa lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT cavallarilarisah lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT sumfestjill lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT wiisanenkristin lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan
AT cicaliemilyj lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan